학술논문
Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China
Document Type
article
Author
Jun Guo; Jiayong Wu; Lihua Wang; Hongbo Liu; Xiaomu Wu; Huan Yang; Wenyu Li; Honghao Wang; Bitao Bu; Chunsheng Yang; Hongyu Zhou; Shougang Guo; Yinan Zhao; Zhanhang Wang; Chunyang Li; De-Cai Tian; Sheng Chen; Huiru Xue; Yanlin Zhang; Yongfeng Xu; Hui Liang; Zhe Wu; Yu Zhang; Qiang Dong; Jiawei Wang; Chao Quan
Source
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Subject
Language
English
ISSN
1756-2864
17562864
17562864
Abstract
Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the first oral DMT was approved in 2018, DMT approval accelerated, and seven DMTs were approved within 5 years. With an increasing number of DMTs being prescribed in clinical practice, it is necessary to discuss the standardized MS treatment algorithms depending on the disease activity and DMT availability. In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country.